An observational study in Tricuspid Valve Regurgitation, Pacemaker and ICD, sponsored by Hazem Omran. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Hazem Omran · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 18th largest by planned enrollment of the 26 observational ones that give a count, is one of 5 that started in 2024, is one of 26 observational ones, reaches primary completion later than 17 of the 30 other live ones, and was the 49th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Germany, United States, France and 2 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
Cardiovalve Ltd. · Sites in Germany
Ages 18–85
Heart and Diabetes Center North-Rhine Westfalia · Sites in Germany
Ages 18+
Robert Bosch Medical Center · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 200 is below the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 60 across the 25 interventional studies, 506 across the 26 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 51 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hazem Omran as lead sponsor.
Hazem Omran has 1 study filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
6 of the studies in Tricuspid Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825898Ottawa Heart Institute Research CorporationOutcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment | 2026-12 |
| NCT07464106Robert Bosch Medical CenterEvaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults. | 2026-12 |
| NCT06212193Innoventric LTDInnoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | 2026-12-20 |
| NCT05797519VDyne, Inc.Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation | 2026-12-30 |
| NCT07342036Hazem OmranProspective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion | 2027-01-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to record the incidence of newly developed or worsening tricuspid valve regurgitation (TR) following the implantation of a pacemaker or defibrillator with a transvenous lead. To collect this data, a transthoracic echocardiogram (TTE) with 3D imaging of the tricuspid valve (TV) will be performed before and after pacemaker implantation, with particular emphasis on assessing the tricuspid valve. Additionally, routine follow-up visits will be conducted at 6 and 12 months post-intervention, during which a TTE, ECG, NT-proBNP measurement, and pacemaker check will be performed.
The prevalence of tricuspid regurgitation (TR) in patients with a pacemaker or ICD/CRT device varies widely, ranging from 5% to 45% across different study protocols. To date, only retrospective analyses have shown that implantation of a device with a transvalvular lead can cause or worsen TR, highlighting the importance of early diagnosis. The aim of this study is to prospectively evaluate patients indicated for cardiac electronic device implantation to document the incidence of newly developed regurgitation (greater than trace) or worsening of existing regurgitation (by at least one grade). Additionally, the study will investigate predictive factors for the development or progression of TR.
patients who have been indicated to have a new cardiac device with a transvalvular probe implanted for any given indication
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Only pacemaker with standard positioning (no ICD leads, no LBBaP)
any ICD leads through tricuspid valve
Left bundle branch area pacing leads
Worsening of TR of at least 1 grade
Worsening of tricuspid regurgitation of at least one grade from baseline before lead insertion through tricuspid valve
Time frame: over the sutdy period up to 1 year after lead insertion
TR > mild at follow-up
The percentage of patients with at least moderate TR or worse
Time frame: during study time frame up to 1 year after Pacemaker/ICD implantation
NTproBNP change from baseline
Change in NTproBNP levels from baseline to 6 and 12 Months
Time frame: at 6 and at 12 months after Pacemaker/ICD implantation
Hospitalization for heart failure (HFH)
Any uplanned hopsitalization with requirement of iv diuretics therapy after inclusion
Time frame: up to 12 months after Pacemaker/ICD implantation
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 29 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →